Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Next Previous
X
Search
Trial Profile

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alectinib (Primary) ; Atezolizumab (Primary) ; Brigatinib (Primary) ; Cobimetinib (Primary) ; Entrectinib (Primary) ; Erlotinib (Primary) ; Everolimus (Primary) ; Ipatasertib (Primary) ; Ipilimumab (Primary) ; Itacitinib (Primary) ; Lapatinib (Primary) ; Nivolumab (Primary) ; Palbociclib (Primary) ; Pemigatinib (Primary) ; Pertuzumab (Primary) ; Ponatinib (Primary) ; Trastuzumab (Primary) ; Trastuzumab emtansine (Primary) ; Vemurafenib (Primary) ; Vismodegib (Primary)
  • Indications Advanced breast cancer; Gastrointestinal cancer; Male breast cancer; Non-small cell lung cancer; Solid tumours
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ROME

    • Most Recent Events

    • 04 Jun 2024 Results (n=425) assessing the prevalence of actionable variants identified and the personalized treatment received by the patients enrolled presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 02 Oct 2023 Planned End Date changed from 1 Aug 2024 to 1 Jun 2025.
    • 02 Oct 2023 Planned primary completion date changed from 1 Apr 2024 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top